US Stock MarketDetailed Quotes
ADMA ADMA Biologics
- 17.400
- -0.500-2.79%
Close Dec 20 16:00 ET
- 17.400
- 0.0000.00%
Post 20:01 ET
4.11BMarket Cap64.44P/E (TTM)
17.960High17.080Low6.94MVolume17.160Open17.900Pre Close121.09MTurnover2.99%Turnover RatioLossP/E (Static)236.39MShares23.64052wk High17.74P/B4.04BFloat Cap4.27052wk Low--Dividend TTM232.07MShs Float23.640Historical High--Div YieldTTM4.92%Amplitude1.010Historical Low17.444Avg Price1Lot Size
ADMA Biologics Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 108.83%25.03M | 853.36%45.65M | 84.94%-2.22M | 114.79%8.8M | 338.47%17.6M | 190.22%11.99M | 52.78%-6.06M | 43.40%-14.72M | 47.04%-59.51M | 77.95%-7.38M |
| Net income from continuing operations | 1,299.42%35.91M | 603.25%32.06M | 362.28%17.81M | 57.15%-28.24M | -44.26%-17.65M | 117.22%2.57M | 53.72%-6.37M | 72.85%-6.79M | 8.02%-65.9M | 26.54%-12.23M |
| Operating gains losses | -91.40%8K | --1K | 27.78%23K | 271.37%26.36M | 6,168.94%26.25M | 1,511.79%93K | --0 | -99.73%18K | 3,111.31%7.1M | 197.93%418.65K |
| Depreciation and amortization | -7.27%1.94M | -2.43%2.05M | 3.98%2.11M | 17.14%8.33M | 8.91%2.11M | 12.35%2.09M | 21.67%2.1M | 27.84%2.03M | 29.42%7.11M | 27.55%1.94M |
| Other non cash items | -87.13%216K | -88.28%192K | -84.85%217K | 19.59%6.29M | 7.47%1.54M | -12.77%1.68M | 21.14%1.64M | 160.77%1.43M | 199.71%5.26M | 206.66%1.43M |
| Change In working capital | -520.20%-16.22M | 267.58%8.48M | -95.73%-24.52M | 44.64%-10.12M | 99,630.52%3.6M | 210.63%3.86M | -51.80%-5.06M | -9.33%-12.53M | 64.62%-18.29M | 99.98%-3.62K |
| -Change in receivables | -469.98%-20.03M | 290.99%19.51M | -101.58%-22.2M | -191.16%-11.92M | -27.78%3.9M | 368.16%5.41M | -251.41%-10.21M | -473.67%-11.01M | 185.22%13.07M | 165.95%5.4M |
| -Change in inventory | 699.48%8.01M | -194.24%-2.08M | -584.54%-4.83M | 75.03%-9.63M | -2,571.53%-9.79M | 92.07%-1.34M | 131.82%2.21M | 95.11%-705K | 10.73%-38.56M | 96.54%-366.46K |
| -Change in prepaid assets | -5,961.11%-4.36M | 59.88%-869K | -39.20%611K | 232.65%841K | 919.25%2.07M | 84.40%-72K | -264.94%-2.17M | 361.82%1.01M | 79.34%-634K | -63.53%203.48K |
| -Change in payables and accrued expense | 1,041.60%1.43M | -249.88%-7.82M | 174.92%1.22M | 36.42%11.37M | 249.99%7.65M | -99.22%125K | 316.27%5.22M | -1,711.76%-1.63M | -14.06%8.33M | -150.28%-5.1M |
| -Change in other current liabilities | -371.75%-1.27M | -145.71%-258K | 462.03%677K | -57.57%-791K | -68.39%-230K | -143.61%-269K | 27.05%-105K | -68.37%-187K | -329.22%-502K | -222.55%-136.59K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 108.83%25.03M | 853.36%45.65M | 84.94%-2.22M | 114.79%8.8M | 338.47%17.6M | 190.22%11.99M | 52.78%-6.06M | 43.40%-14.72M | 47.04%-59.51M | 77.95%-7.38M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -45.05%-1.1M | -171.22%-2.37M | -21.44%-2.36M | 64.19%-4.98M | 62.46%-1.41M | 77.61%-757K | 77.87%-872K | 31.56%-1.95M | -2.96%-13.91M | -1.98%-3.75M |
| Net PPE purchase and sale | -39.50%-1.06M | -136.93%-2.07M | -20.67%-2.35M | 65.70%-4.77M | 68.07%-1.2M | 77.61%-757K | 77.87%-872K | 31.56%-1.95M | -2.96%-13.91M | -1.98%-3.75M |
| Net intangibles purchase and sale | ---42K | ---299K | ---15K | ---210K | ---210K | --0 | --0 | --0 | --0 | ---- |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -45.05%-1.1M | -171.22%-2.37M | -21.44%-2.36M | 64.19%-4.98M | 62.46%-1.41M | 77.61%-757K | 77.87%-872K | 31.56%-1.95M | -2.96%-13.91M | -1.98%-3.75M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -6,221.88%-25.47M | -250.83%-362K | -122.62%-1.45M | -135.82%-38.99M | -162.15%-39M | 149.30%416K | 175.23%240K | -101.38%-650K | -10.08%108.85M | 16.58%62.74M |
| Net issuance payments of debt | ---30M | --0 | --0 | -145.64%-23.6M | -270,401.20%-23.59M | --0 | 34.02%-6K | -100.02%-10K | 152,200.00%51.71M | -2.66%-8.72K |
| Net common stock issuance | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | -46.64%64.65M | ---- |
| Proceeds from stock option exercised by employees | 812.02%5.69M | -29.87%331K | --1.03M | 530.86%1.1M | -95.43%8K | --624K | --472K | --0 | --175K | --175K |
| Net other financing activities | -456.73%-1.16M | -206.64%-693K | -286.88%-2.48M | -114.68%-16.49M | -645.63%-15.42M | 75.08%-208K | 27.08%-226K | 85.68%-640K | -12,290.32%-7.68M | -514,271.89%-2.07M |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -6,221.88%-25.47M | -250.83%-362K | -122.62%-1.45M | -135.82%-38.99M | -162.15%-39M | 149.30%416K | 175.23%240K | -101.38%-650K | -10.08%108.85M | 16.58%62.74M |
| Net cash flow | ||||||||||
| Beginning cash position | 41.16%88.24M | -34.51%45.33M | -40.65%51.35M | 69.36%86.52M | 112.45%74.16M | 19.27%62.51M | -0.43%69.2M | 69.36%86.52M | -8.64%51.09M | 1.44%34.91M |
| Current changes in cash | -113.20%-1.54M | 741.44%42.92M | 65.20%-6.03M | -199.26%-35.17M | -144.18%-22.81M | 166.50%11.64M | 60.85%-6.69M | -194.04%-17.32M | 833.30%35.43M | 209.48%51.62M |
| End cash Position | 16.92%86.71M | 41.16%88.24M | -34.51%45.33M | -40.65%51.35M | -40.65%51.35M | 112.45%74.16M | 19.27%62.51M | -0.43%69.2M | 69.36%86.52M | 69.36%86.52M |
| Free cash flow | 113.13%23.93M | 724.46%43.28M | 72.52%-4.58M | 105.20%3.82M | 245.50%16.19M | 167.37%11.23M | 58.67%-6.93M | 42.24%-16.67M | 41.68%-73.42M | 70.04%-11.13M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- |
Heat List
US
Overall
Symbol
Price
% Chg
No Data